This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sarizotan

Newron Pharmaceuticals SpA

Drug Names(s): EMD128130

Description: Sarizotan is a serotonin 1A (5-HT1A) receptor agonist. Brain cells producing brain chemicals such as serotonin exhibit damage in Parkinson's disease, accounting for some of the wide array of symptoms.

Deal Structure: Newron and Merck KGaA
In March 2011, Newron and Merck KGaA announced a broadening of the scope of their collaboration. Under the terms of the agreement, Newron received a development licence for two Merck clinical-stage compounds,pruvanserin and sarizotan. Merck will retain buy-back options for each compound, exercisableupon completion of proof of concept trials. Should these options be exercised by Merck,Newron will have a co-development option.

Newron and Biotie
In September 2011, Biotie Therapies and Newron Pharmaceuticals announced that they signed an agreement for Biotie to acquire Newron. In October 2011, Biotie notified Newron of its decision to exercise its right to terminate the Merger Plan and combination agreement, without further obligations from Biotie.

Partners: Merck KGaA


Sarizotan News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug